BR0015802A - Sistema de administração de contraceptivo transdérmico, e, método para controlar a fertilidade, e para produzir um sistema de administração de contracptivo transdérmico - Google Patents

Sistema de administração de contraceptivo transdérmico, e, método para controlar a fertilidade, e para produzir um sistema de administração de contracptivo transdérmico

Info

Publication number
BR0015802A
BR0015802A BR0015802-0A BR0015802A BR0015802A BR 0015802 A BR0015802 A BR 0015802A BR 0015802 A BR0015802 A BR 0015802A BR 0015802 A BR0015802 A BR 0015802A
Authority
BR
Brazil
Prior art keywords
transdermal
administration system
transdermal contraceptive
fertility
contraceptive administration
Prior art date
Application number
BR0015802-0A
Other languages
English (en)
Other versions
BR0015802B1 (pt
Inventor
Te-Yen Chien
Original Assignee
Agile Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agile Therapeutics Inc filed Critical Agile Therapeutics Inc
Publication of BR0015802A publication Critical patent/BR0015802A/pt
Publication of BR0015802B1 publication Critical patent/BR0015802B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"SISTEMA DE ADMINISTRAçãO DE CONTRACEPTIVO TRANSDéRMICO, E, MéTODOS PARA CONTROLAR A FERTILIDADE, E PARA PRODUZIR UM SISTEMA DE ADMINISTRAçãO DE CONTRACEPTIVO TRANSDéRMICO". Descreve-se um sistema de administração de contraceptivo transdérmico (TCDS) para controle da fertilidade em mulheres, compreendendo uma camada de apoio, uma camada contígua de uma matriz polimérica adesiva de absorção sólida, em que doses diárias eficazes mínimas de um estrogênio e uma progestina são dispersas e liberadas para absorção transdérmica. é presentemente preferido o uso do estrogênio sintético, etinil estradiol, e da progestina sintética, levonorgestrel. Juntamente com estes dois agentes contraceptivos esteróides, uma combinação de diversos agentes químicos, intensificadores da permeação na pele, incluindo ácido cáprico, misturados em relações de peso específicas, variando de 2,0:1:1:0,8 a 6:1:1:0,8, é homogeneamente dispersa na matriz polimérica adesiva. A invenção também provê um método de controle da fertilidade, utilizando o sistema de administração de contraceptivo transdérmico.
BRPI0015802-0B1A 1999-11-24 2000-11-22 Sistema de administração de contraceptivo transdérmico, e, método para produzir um sistema de administração de contraceptivo transdérmico BR0015802B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16753599P 1999-11-24 1999-11-24
US60/167535 1999-11-24
PCT/US2000/032043 WO2001037770A1 (en) 1999-11-24 2000-11-22 Improved transdermal contraceptive delivery system and process

Publications (2)

Publication Number Publication Date
BR0015802A true BR0015802A (pt) 2003-06-24
BR0015802B1 BR0015802B1 (pt) 2014-04-29

Family

ID=22607771

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0015802-0B1A BR0015802B1 (pt) 1999-11-24 2000-11-22 Sistema de administração de contraceptivo transdérmico, e, método para produzir um sistema de administração de contraceptivo transdérmico

Country Status (21)

Country Link
EP (1) EP1242012B1 (pt)
JP (2) JP4841781B2 (pt)
KR (1) KR100758757B1 (pt)
CN (1) CN1399533A (pt)
AR (1) AR030037A1 (pt)
AT (1) ATE453374T1 (pt)
AU (2) AU784196B2 (pt)
BR (1) BR0015802B1 (pt)
CA (1) CA2391430C (pt)
CY (1) CY1110615T1 (pt)
DE (1) DE60043621D1 (pt)
DK (1) DK1242012T3 (pt)
ES (1) ES2338860T3 (pt)
IL (1) IL149655A0 (pt)
MX (1) MXPA02005224A (pt)
NO (1) NO331218B1 (pt)
NZ (1) NZ518723A (pt)
PT (1) PT1242012E (pt)
TW (1) TWI253350B (pt)
WO (1) WO2001037770A1 (pt)
ZA (1) ZA200203525B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
DE10159120B4 (de) * 2001-12-01 2006-08-17 Lts Lohmann Therapie-Systeme Ag Steroidhormonhaltige transdermale therapeutische Systeme enthaltend Propylenglycolmonocaprylat und seine Verwendung
PL219030B1 (pl) 2003-02-21 2015-03-31 Schering Ag Transdermalny system terapeutyczny w postaci plastra odporny na działanie promieniowania UV
JP2006525358A (ja) * 2003-05-02 2006-11-09 ドゥラメド ファーマシューティカルズ， インコーポレイテッド 長期周期避妊養生法を利用するホルモン治療の方法
UA84303C2 (ru) * 2003-10-28 2008-10-10 Новен Фармасьютикалз, Инк. Система для трансдермальной доставки лечебного средства
UA89766C2 (en) 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
US20050202073A1 (en) 2004-03-09 2005-09-15 Mylan Technologies, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US9205062B2 (en) 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
CN1313084C (zh) * 2004-11-05 2007-05-02 郑会义 一种透皮避孕药传送体系及制备方法
CN1318032C (zh) * 2005-01-24 2007-05-30 浙江大学 炔雌醇透皮吸收贴片
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
US20080075779A1 (en) * 2006-09-27 2008-03-27 Chappa Ralph A Additives And Methods For Enhancing Active Agent Elution Kinetics
GB0809905D0 (en) * 2008-06-02 2008-07-09 Secr Defence A Transdermal drug delivery device
WO2011048613A2 (en) 2009-10-12 2011-04-28 Lyka Labs Limited Emergency contraceptive
US20110236462A1 (en) 2010-03-28 2011-09-29 Shaked Ze Ev Intravaginal drug delivery device
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
US10028858B2 (en) 2011-07-11 2018-07-24 Medicines360 Intrauterine systems, IUD insertion devices, and related methods and kits therefor
CA2854164C (en) * 2011-11-04 2021-04-13 Agile Therapeutics, Inc. Dermal delivery compositions and methods
US9144553B2 (en) 2012-12-21 2015-09-29 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents
US9314470B2 (en) 2012-12-28 2016-04-19 Noven Pharmaceuticals, Inc. Transdermal drug delivery systems for levonorgestrel and ethinyl estradiol

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632740A (en) * 1968-06-13 1972-01-04 Johnson & Johnson Topical device for the therapeutic management of dermatological lesions with steroids
JPS5843368B2 (ja) * 1980-10-30 1983-09-27 日東電工株式会社 消炎鎮痛貼付剤
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
EP0721348B1 (en) * 1993-09-29 1999-09-01 Alza Corporation Monoglyceride/lactate ester permeation enhancer
EP0742011B1 (en) * 1994-11-17 2002-07-24 Toray Industries, Inc. Percutaneously absorbable preparation
PL181582B1 (pl) * 1995-06-07 2001-08-31 Ortho Mcneil Pharm Inc Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL
US5762956A (en) * 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process

Also Published As

Publication number Publication date
JP4841781B2 (ja) 2011-12-21
CY1110615T1 (el) 2015-04-29
PT1242012E (pt) 2010-03-31
JP2011231125A (ja) 2011-11-17
BR0015802B1 (pt) 2014-04-29
NO331218B1 (no) 2011-11-07
CA2391430A1 (en) 2001-05-31
NO20022420L (no) 2002-07-18
ZA200203525B (en) 2003-07-18
AR030037A1 (es) 2003-08-13
AU2006201918B2 (en) 2009-07-30
TWI253350B (en) 2006-04-21
NZ518723A (en) 2004-04-30
KR100758757B1 (ko) 2007-09-14
DE60043621D1 (de) 2010-02-11
NO20022420D0 (no) 2002-05-22
JP2003533434A (ja) 2003-11-11
KR20020072280A (ko) 2002-09-14
AU784196B2 (en) 2006-02-23
EP1242012B1 (en) 2009-12-30
CA2391430C (en) 2009-10-06
DK1242012T3 (da) 2010-04-26
MXPA02005224A (es) 2003-09-25
IL149655A0 (en) 2002-11-10
WO2001037770A1 (en) 2001-05-31
EP1242012A4 (en) 2006-05-31
ATE453374T1 (de) 2010-01-15
EP1242012A1 (en) 2002-09-25
AU1788301A (en) 2001-06-04
AU2006201918A1 (en) 2006-06-01
ES2338860T3 (es) 2010-05-13
CN1399533A (zh) 2003-02-26

Similar Documents

Publication Publication Date Title
BR0015802A (pt) Sistema de administração de contraceptivo transdérmico, e, método para controlar a fertilidade, e para produzir um sistema de administração de contracptivo transdérmico
EP1089722B1 (en) Matrix-type transdermal patch for steroid hormones
KR970701039A (ko) 성 스테로이드를 함유하는 경피 치료 시스템(Sexual Steroid-Containing Transdermal Therapeutic Systems)
JP3422796B2 (ja) ステロイドの安定性を向上させるための薬剤放出組成物
AU709286B2 (en) Transdermal estradiol/progestogen agent patch and its production
CA2626567C (en) Method of preventive on-demand hormonal contraception
AU618114B2 (en) Multilayer plaster
ES2249763T5 (es) Sistema de administracion transdermica de farmaco potente de flujo bajo.
US5820878A (en) Percutaneously absorbable patch
CA2259532C (en) Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5891920A (en) Medicinal adjuvants consisting of N-subsitituted-o-toluidine derivatives, and percutaneously absorbable preparations comprising the adjuvants
PT836506E (pt) Penso transdermico para administracao de 17-desacetil norgestimato so ou em combinacao com um estrogenio
KR900005969A (ko) 게스토덴을 함유하는 경피 투여용 제제
AU635182B2 (en) Transdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration
KR910700044A (ko) 에스트로겐/프로게스틴 경피용량 단위, 시스템 및 방법
ES2074982T3 (es) Unidad de dosificacion transdermica de estrogeno/progestina, y estuche de control de la fertilidad que comprende dicha unidad de dosificacion.
PT99338A (pt) Processo para a preparacao de composicoes de farmacos anticoncepcionais administradas transdermicamente contendo uma mistura dum estrogeno e gestodeno e dispositivos para a sua administracao transdermica
HRP20100254T1 (hr) Transdermalni sustav za davanje gestodena
EP1390041A1 (en) Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
HUP0402213A2 (hu) Propilénglikolmonokaprilátot tartalmazó szteroid hormontartalmú transzdermális terápiás rendszer
BR9912466A (pt) Utilização de sulfamatos de estrogênio biogênicos na terapia de reposição hormonal
Sitruk-Ware Transdermal application of steroid hormones for contraception
BRPI0417530A (pt) liberação transdérmica de hormÈnios sem a necessidade de melhoradores de penetração
KUMASAKA et al. Effects of various forms of progestin on the endometrium of the estrogen-primed, ovariectomized rat
Ibarra de Palacios et al. Comparative study to evaluate skin irritation and adhesion of Estradot® and Climara® in healthy postmenopausal women

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61F 13/00, A61F 13/02, A61L 15/16

Ipc: A61K 9/70 (2009.01), A61K 9/00 (2009.01), A61K 31/

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/04/2014, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2541 DE 17-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.